Who
Sandra Horning
Director
Company insider
Files Form 4 as: Director, Revolution Medicines; Director, Olema Pharmaceuticals; Director, Moderna; Director, Gilead Sciences; Director, EQRx.
In numbers
- Trades disclosed
- 79
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 28 Jan 2020
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,127 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —1,191 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,681 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,092 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,681 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,092 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,146 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,884 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,884 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,146 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —16,233 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,233 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,233 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —16,233 | filing |
| 26 Jun 2025filed 30 Jun 2025 | RVMD Revolution Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,574 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | RVMD Revolution MedicinesBiotechnology | SEC FORM 4 Code A | —3,142 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.